Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F. Ferreira JP, et al. Among authors: shi h. Clin Res Cardiol. 2018 Jan;107(1):49-59. doi: 10.1007/s00392-017-1157-3. Epub 2017 Aug 29. Clin Res Cardiol. 2018. PMID: 28852839 Clinical Trial.
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Eschalier R, et al. Among authors: shi h. J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27. J Am Coll Cardiol. 2013. PMID: 23810881 Free article. Clinical Trial.
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Rossignol P, et al. Among authors: shi h. Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F; REMINDER Investigators; REMINDER Investigators. Montalescot G, et al. Among authors: shi h. Eur Heart J. 2014 Sep 7;35(34):2295-302. doi: 10.1093/eurheartj/ehu164. Epub 2014 Apr 29. Eur Heart J. 2014. PMID: 24780614 Clinical Trial.
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B. Rossignol P, et al. Among authors: shi h. Eur J Heart Fail. 2017 Jun;19(6):792-799. doi: 10.1002/ejhf.688. Epub 2016 Nov 20. Eur J Heart Fail. 2017. PMID: 27868385 Free article. Clinical Trial.
Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.
Ferreira JP, Barros A, Pitt B, Montalescot G, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Leite-Moreira A, Vincent J, Rossignol P, Zannad F. Ferreira JP, et al. Among authors: shi h. Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27. Clin Res Cardiol. 2018. PMID: 30264283 No abstract available.
Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Zannad F, et al. Among authors: shi h. N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14. N Engl J Med. 2011. PMID: 21073363 Free article. Clinical Trial.
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Collier TJ, et al. Among authors: shi h. Eur Heart J. 2013 Sep;34(36):2823-9. doi: 10.1093/eurheartj/eht247. Epub 2013 Jul 17. Eur Heart J. 2013. PMID: 23864130 Clinical Trial.
15,040 results
You have reached the last available page of results. Please see the User Guide for more information.